Sunshine Heart (NASDAQ:CHFS) is scheduled to post its quarterly earnings results before the market opens on Tuesday, March 20th.
Shares of Sunshine Heart (NASDAQ CHFS) traded down $0.03 during trading on Wednesday, reaching $3.82. 172,114 shares of the company’s stock traded hands, compared to its average volume of 467,301. The company has a market cap of $6.36, a price-to-earnings ratio of -0.03 and a beta of 2.31. Sunshine Heart has a 12-month low of $2.87 and a 12-month high of $75.60.
Separately, Zacks Investment Research lowered shares of Sunshine Heart from a “buy” rating to a “hold” rating in a report on Thursday, January 11th.
Sunshine Heart Company Profile
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.